Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation (Nasdaq: BRKR) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q, and other key documents. These filings offer detailed information on Bruker’s financial condition, operating performance, capital structure, and material corporate events.
Bruker’s Form 8-K filings illustrate how the company reports significant developments such as quarterly and interim financial results, material modifications to security holder rights, and securities offerings. For example, Bruker has filed 8-Ks to furnish press releases with results of operations and financial condition for specific quarters, and to describe the issuance and terms of its 6.375% Mandatory Convertible Preferred Stock, Series A. That filing outlines the preferred stock’s dividend rate, liquidation preference, conversion mechanics into common stock, and related restrictions on dividends and share repurchases affecting junior and parity stock.
Through Forms 10-K and 10-Q, users can review segment information for Bruker Scientific Instruments and the Bruker Energy & Supercon Technologies (BEST) division, along with discussions of markets served, risk factors, and management’s analysis of results. These filings also describe how Bruker’s scientific instruments and diagnostic solutions support life science, applied, biopharma, industrial and cleantech research, and semiconductor metrology applications.
On this page, Stock Titan enhances Bruker’s raw SEC filings with AI-powered summaries that explain complex sections in plain language. Users can quickly understand the implications of Bruker’s 10-K and 10-Q reports, preferred stock terms, and other material events, while still having direct access to the original EDGAR documents. Filings related to insider transactions on Form 4 and proxy materials on Schedule 14A can also be monitored to track executive equity activity and governance matters over time.
Bruker Corp director Adelene Q. Perkins received an equity award of 4,520 restricted stock units (RSUs) of Common Stock on February 15, 2026. The RSUs will vest in a single installment on February 15, 2027, and each unit will convert into one share of Common Stock at vesting. After this grant, Perkins beneficially owns 29,144 shares of Common Stock directly.
BRUKER CORP director Richard A. Packer received an equity award covering 4,520 shares of common stock as a grant of Restricted Stock Units. The RSUs will vest in a single installment on February 15, 2027, at which time each unit will convert into one share of common stock. After this award, Packer’s directly held common stock, including this grant, is reported at 93,694 shares. The grant was recorded at a price of $0.00 per share, consistent with a stock-based compensation award rather than an open-market purchase.
BRUKER CORP director Cynthia M. Friend reported an equity award of 4,520 units tied to Common Stock. The award is structured as Restricted Stock Units (RSUs) that were granted at no cash cost on the transaction date. All 4,520 RSUs will vest in a single installment on February 15, 2027, and each RSU will automatically convert into one share of Common Stock at that time. Following this grant, she now directly holds 22,536 shares of Common Stock, reflecting her updated ownership position.
BRUKER CORP director Bob Rosenthal reported an equity award. He acquired 4,520 shares of Common Stock through a grant classified as a grant, award, or other acquisition at a stated price of $0.00 per share.
According to the footnote, this grant is in the form of Restricted Stock Units that will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into one share of Common Stock. After this award, Rosenthal directly holds 38,781 shares of Common Stock.
Bruker Corp director Hermann Fritz Requardt received an equity grant of 4,520 shares of Common Stock in the form of restricted stock units. The award was granted at a price of $0.00 per share on February 15, 2026 as compensation rather than an open-market purchase.
The RSUs will vest in one installment on February 15, 2027, at which time each unit will automatically convert into one share of Bruker Common Stock. Following this grant, Requardt holds 30,965 shares of Common Stock in direct ownership, aligning his interests more closely with shareholders.
BRUKER CORP Chief Accounting Officer Thomas Bures reported a tax-related share disposition. On the reported date, 274 shares of common stock were withheld at a price of $36.51 per share to satisfy tax withholding obligations tied to previously granted restricted stock units that vested. After this withholding transaction, Bures directly owned 3,198 shares of Bruker common stock, reflecting a routine, non-open-market adjustment for taxes rather than an elective share sale.
Bruker Corp executive Mark Munch reported option exercises and a share sale. On February 13, he exercised stock options for 2,000 shares, converting derivative securities into common stock at a price of $22.19 per share. He then sold 2,000 common shares at $36.94 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan.
Following these transactions, he directly owned 128,443 shares of Bruker common stock and held 14,000 stock options.
BRUKER CORP director Bonnie H. Anderson reported an equity award of 4,520 shares of Common Stock. The award was made at a price of $0.00 per share as a grant or other acquisition. Following this award, she reports beneficial ownership of 17,847 Common Stock shares.
According to the filing, the grant is in the form of Restricted Stock Units that will vest in a single installment on February 15, 2027. On that vesting date, each RSU will automatically convert into an equal number of shares of Bruker common stock.
Bruker Corp received an updated ownership report showing that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, and Orbis Investment Management (U.S.) L.P. together beneficially own 14,906,730 shares of Bruker common stock, representing 9.8% of the outstanding class.
Orbis Investment Management Ltd reports sole voting and dispositive power over 14,077,895 shares, Allan Gray Australia over 22,092 shares, and Orbis Investment Management (U.S.) L.P. over 806,743 shares. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Bruker.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of 4,594,398 shares of Bruker Corp common stock, representing 3.0% of the class as of 12/31/2025. The firm has sole voting power over 4,584,656 shares and sole dispositive power over 4,594,398 shares, with no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Bruker. The filer also affirms that this should not be construed as an admission of beneficial ownership, which is expressly denied.